UP!

EW $65.81

EW target price
65.81
0
128
Edwards Lifesciences
Type
Public
Traded as NYSE: EW
S&P 500 Component
Industry Medical device
Founded 1958; 59 years ago (1958)
Headquarters Irvine, California, United States
Key people
Michael A. Mussallem, Chairman & CEO
Products Heart valves, Critical care technology, Cardiac surgery technology
Revenue $2.49 billion (2015)
Number of employees
8,700
Website Edwards.com

Edwards Lifesciences is an American medical equipment company specializing in artificial heart valves and hemodynamic monitoring. It is mostly known for a transcatheter aortic heart valve made of bovine tissue within a collapsible stainless-steel stent, deployed via catheter. Their SAPIEN product is an FDA-approved device for percutaneous aortic valve replacement. It is publicly traded on the NYSE under the symbol EW.

Edwards Lifesciences’ roots date to 1958, when Miles “Lowell” Edwards set out to build the first artificial heart.

Edwards was a 60-year-old, recently retired engineer holding 63 patents in an array of industries, with an entrepreneurial spirit and a dream of helping patients with heart disease. His fascination with healing the heart was sparked in his teens, when he suffered two bouts of a disease called rheumatic fever, which can scar heart valves and eventually cause the heart to fail.

With a background in hydraulics and fuel pump operations, Edwards believed the human heart could be mechanized. He presented the idea to Dr. Albert Starr, a young surgeon at the University of Oregon Medical School, who thought the idea was too complex. Instead, Starr encouraged Edwards to focus first on developing an artificial heart valve, for which there was an immediate need.

After just two years, the first Starr-Edwards mitral valve was designed, developed, tested, and successfully placed in a patient. Newspapers around the world reported on what they termed a “miraculous” heart surgery.

This innovation spawned a company, Edwards Laboratories, which set up shop in Santa Ana, California – not far from where Edwards Lifesciences’ corporate headquarters is located today.

In 1966, Edwards Laboratories was purchased by American Hospital Supply Corporation and became American Edwards Laboratories. Then, in 1985, American Edwards was acquired by Baxter International Inc. In early 2000, the company was spun off as an independent, publicly held corporation and began trading on the New York Stock Exchange under the symbol “EW.”

Today, Edwards continues as a leader in the field of tissue replacement heart valves and repair products and advanced hemodynamic monitoring, which have helped treat and manage more than 2 million patients worldwide. Each year, more than 300,000 valve replacements are performed worldwide through open-heart surgery, utilizing either bioprosthetic tissue valves or mechanical valves. Edwards products include tissue replacement heart valves, sold under such brand names as Carpentier-Edwards PERIMOUNT and Carpentier-Edwards PERIMOUNT MAGNA, and also valve repair products that are used by surgeons to fix, instead of replace, a patient’s valve.

The Edwards SAPIEN family of heart valves are delivered via a procedure called transcatheter aortic valve replacement (TAVR). This procedure enables the placement of a collapsible heart valve into the body via a tube-based delivery system (catheter) that can be inserted through multiple access routes, including either an incision in the leg (transfemoral), or in between the ribs and to be threaded up to the heart (transapical), or through the front of the chest and then through a small hole in the aorta (transaortic). The valve is designed to replace a patient’s diseased native aortic valve without traditional open-heart surgery and while the heart continues to beat – avoiding the need to stop the patient’s heart and connect them to a heart-lung machine that temporarily takes over the function of the heart and the patient’s breathing during surgery (cardiopulmonary bypass).

Edwards also manufactures products for vascular therapy along with hemodynamic monitoring devices for measuring cardiovascular performance during surgery and in the ICU. Hemodynamic monitoring is the measurement of blood circulation and cardiac function that allows clinicians to evaluate whether enough oxygen is being delivered to the organs and tissues. Among these is the Swan-Ganz catheter. Originally developed for patients with acute myocardial infarction, it is now used in anesthesia and critical care units. Healthcare providers use this monitoring to detect changes or problems in a patient’s health, which allows for more informed, immediate treatment decisions.

To facilitate on-pump cardiac surgery procedures through smaller incisions, Edwards also offers a cardiac surgery product line comprising soft tissue retractors, venous and arterial cannulae, aortic occlusion, venting, and coronary sinus catheters, as well as reusable instruments for performing minimally invasive valvular procedures.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2022 2023-04-26 Future report Set alerts
Q3 2022 2022-10-27 0.61 0.61
Q2 2022 2022-07-28 0.63 0.63
Q1 2022 2022-04-26 0.60 0.60
Q4 2021 2022-01-26 0.51 0.51
Q3 2021 2021-10-27 0.54 0.54
Q2 2021 2021-07-29 0.64 0.64
Q1 2021 2021-04-20 0.54 0.54
Q4 2020 2021-01-27 0.50 0.50
Q3 2020 2020-10-21 0.51 0.51

Ratings

2016-07-12 Reiterated Rating JPMorgan Chase & Co. Buy
2016-06-21 Reiterated Rating Piper Jaffray Overweight $123.00
2016-06-21 Reiterated Rating William Blair Outperform
2016-06-21 Reiterated Rating Piper Jaffray Cos. Overweight $123.00
2016-06-08 Reiterated Rating Credit Suisse Buy
2016-06-08 Initiated Coverage Guggenheim Neutral
2016-06-08 Reiterated Rating Credit Suisse Group AG Buy
2016-06-01 Reiterated Rating JMP Securities Mkt Perform
2016-06-01 Reiterated Rating Canaccord Genuity Buy $132.00
2016-05-25 Reiterated Rating Piper Jaffray Overweight $123.00
2016-05-23 Boost Price Target Canaccord Genuity Buy $123.00 to $132.00
2016-04-28 Reiterated Rating Piper Jaffray Overweight $97.00 to $123.00
2016-04-27 Reiterated Rating Jefferies Group Buy $105.00 to $125.00
2016-04-27 Reiterated Rating BMO Capital Markets Buy
2016-04-27 Reiterated Rating Morgan Stanley Buy
2016-04-27 Reiterated Rating Leerink Swann Buy $115.00 to $125.00
2016-04-27 Boost Price Target Canaccord Genuity Buy $113.00 to $123.00
2016-04-27 Reiterated Rating RBC Capital Outperform $110.00 to $125.00
2016-04-27 Reiterated Rating Cowen and Company Outperform $105.00 to $120.00
2016-04-27 Reiterated Rating Citigroup Inc. Sell $67.00 to $86.00
2016-04-27 Reiterated Rating Royal Bank Of Canada Outperform $110.00 to $125.00
2016-04-11 Reiterated Rating JPMorgan Chase & Co. Overweight $110.00 to $120.00
2016-04-08 Boost Price Target Goldman Sachs $100.00 to $125.00
2016-04-08 Boost Price Target Goldman Sachs Group Inc. $100.00 to $125.00
2016-04-07 Lower Price Target Barclays Equal Weight $105.00 to $87.00
2016-04-07 Lower Price Target Barclays PLC Equal Weight $105.00 to $87.00
2016-04-06 Reiterated Rating Morgan Stanley Buy
2016-04-06 Reiterated Rating Bank of America Hold $102.00
2016-04-06 Reiterated Rating Bank of America Corp. Hold $102.00
2016-04-05 Downgrade Northland Securities Outperform to Market Perform $105.00
2016-04-04 Boost Price Target Canaccord Genuity Buy $95.00 to $113.00
2016-04-04 Lower Price Target BMO Capital Markets Outperform $114.00 to $93.00
2016-04-04 Lower Price Target Leerink Swann Outperform $115.00 to $93.00
2016-04-04 Boost Price Target Jefferies Group Buy $100.00 to $105.00
2016-04-04 Upgrade BTIG Research Neutral to Buy $115.00
2016-04-04 Reiterated Rating JPMorgan Chase & Co. Overweight $98.00 to $110.00
2016-04-04 Boost Price Target Credit Suisse Outperform $88.00 to $98.00
2016-04-04 Lower Price Target Stifel Nicolaus Buy $117.00 to $98.00
2016-04-04 Boost Price Target RBC Capital Outperform $100.00 to $110.00
2016-04-04 Reiterated Rating Wells Fargo Buy
2016-04-04 Reiterated Rating Barclays Hold $87.00
2016-04-04 Reiterated Rating Wells Fargo & Co. Buy
2016-04-02 Upgrade BTIG Research Neutral to Buy $115.00
2016-03-24 Reiterated Rating Jefferies Group Buy $100.00
2016-03-17 Initiated Coverage Nomura Buy $101.00
2016-03-17 Initiated Coverage Nomura Holdings Inc. Buy $101.00
2016-03-08 Reiterated Rating SunTrust Buy
2016-03-08 Reiterated Rating SunTrust Banks Inc. Buy
2016-03-07 Lower Price Target SunTrust Neutral $100.00 to $88.00
2016-02-26 Reiterated Rating Citigroup Inc. Sell $67.00
2016-02-18 Boost Price Target Canaccord Genuity Buy $92.00 to $95.00
2016-02-03 Reiterated Rating Piper Jaffray Buy $90.00 to $97.00
2016-02-03 Reiterated Rating Wells Fargo Buy
2016-02-03 Reiterated Rating Credit Suisse Buy $88.00
2016-02-03 Boost Price Target Goldman Sachs Buy $91.00 to $96.00
2016-02-03 Reiterated Rating BMO Capital Markets Buy $93.00
2016-02-03 Reiterated Rating Barclays Equal Weight $85.00 to $87.00
2016-02-03 Reiterated Rating Canaccord Genuity Buy $90.00 to $92.00
2016-02-03 Lower Price Target RBC Capital Outperform $100.00 to $93.00
2016-01-21 Reiterated Rating Leerink Swann Outperform $93.00
2016-01-21 Upgrade SunTrust Neutral to Buy $86.00 to $88.00
2016-01-07 Initiated Coverage SunTrust Neutral $86.00
2016-01-06 Initiated Coverage JMP Securities Market Perform
2016-01-05 Initiated Coverage Evercore ISI Hold $84.50
2016-01-04 Reiterated Rating JPMorgan Chase & Co. Buy
2016-01-04 Boost Price Target Sterne Agee CRT Buy $90.00 to $92.00
2015-12-29 Reiterated Rating Credit Suisse Buy
2015-12-29 Boost Price Target JPMorgan Chase & Co. Overweight $84.00 to $98.00
2015-12-23 Reiterated Rating Credit Suisse Outperform $81.00 to $88.00
2015-12-17 Boost Price Target Jefferies Group Buy $90.00 to $100.00
2015-12-15 Reiterated Rating BTIG Research Hold
2015-12-10 Reiterated Rating Canaccord Genuity Buy
2015-12-10 Boost Price Target Stifel Nicolaus Buy $89.50 to $97.50
2015-12-10 Lower Price Target Cowen and Company Outperform $92.50 to $46.50
2015-12-09 Reiterated Rating BTIG Research Neutral
2015-11-13 Boost Price Target Goldman Sachs $83.50 to $88.00
2015-11-12 Initiated Coverage Citigroup Inc. Sell $67.00
2015-10-27 Boost Price Target BMO Capital Markets Outperform $85.00 to $86.50
2015-10-27 Boost Price Target Barclays Equal Weight $77.50 to $80.00
2015-10-26 Reiterated Rating Canaccord Genuity Buy $89.00
2015-10-19 Upgrade Wells Fargo Priority List
2015-10-16 Reiterated Rating Canaccord Genuity Buy $89.00
2015-10-09 Initiated Coverage Cowen and Company Outperform $92.50
2015-09-28 Reiterated Rating RBC Capital Outperform $92.50
2015-08-28 Reiterated Rating Jefferies Group Buy $90.00
2015-08-27 Lower Price Target Goldman Sachs $84.00 to $83.50
2015-08-10 Reiterated Rating Credit Suisse Buy $75.00 to $81.00
2015-07-30 Reiterated Rating Piper Jaffray Overweight $85.00 to $90.50
2015-07-29 Reiterated Rating Canaccord Genuity Buy $89.00
2015-07-29 Reiterated Rating BTIG Research Neutral
2015-07-29 Boost Price Target Barclays Equal Weight $75.00 to $77.50
2015-07-29 Boost Price Target Stifel Nicolaus Buy $78.50 to $89.50
2015-07-13 Reiterated Rating BMO Capital Markets Buy $79.00 to $83.50
2015-07-13 Reiterated Rating BTIG Research Hold
2015-07-13 Upgrade Northland Securities Market Perform to Outperform $70.00 to $85.00
2015-07-13 Upgrade RBC Capital Sector Perform to Outperform $67.50 to $92.50
2015-07-06 Upgrade Morgan Stanley Equal Weight to Overweight $67.50 to $84.00
2015-06-18 Reiterated Rating Canaccord Genuity Buy $80.00
2015-06-09 Upgrade BMO Capital Markets Market Perform to Outperform $79.00
2015-05-19 Set Price Target Canaccord Genuity Buy $80.00
2015-05-12 Upgrade JPMorgan Chase & Co. Neutral to Overweight $73.50 to $77.50
2015-04-27 Boost Price Target Deutsche Bank Hold $66.50 to $70.00
2015-04-27 Boost Price Target Deutsche Bank AG Hold $66.50 to $70.00
2015-04-26 Reiterated Rating BTIG Research Neutral
2015-04-26 Reiterated Rating Canaccord Genuity Buy $80.00
2015-04-24 Boost Price Target Barclays Equal Weight $70.00 to $75.00
2015-03-12 Reiterated Rating Canaccord Genuity Buy $79.50
2015-03-09 Boost Price Target Barclays Equal Weight $58.50 to $65.00
2015-02-04 Reiterated Rating BTIG Research Hold
2015-02-04 Set Price Target Canaccord Genuity Buy $79.50
2015-02-04 Boost Price Target RBC Capital Sector Perform $57.50 to $62.50
2015-01-06 Downgrade Northland Securities Outperform to Market Perform $70.00
2014-12-09 Reiterated Northland Capital Outperform $130 to $140
2014-12-09 Boost Price Target Canaccord Genuity Buy $76.50 to $79.50
2014-12-09 Boost Price Target JPMorgan Chase & Co. Neutral $60.00 to $62.00
2014-12-09 Boost Price Target Deutsche Bank Hold $57.50 to $66.50
2014-12-09 Boost Price Target Barclays Equal Weight $46.00 to $50.00
2014-12-09 Boost Price Target Jefferies Group Buy $60.50 to $77.50
2014-12-09 Boost Price Target Morgan Stanley Equal Weight $60.00 to $65.00
2014-12-09 Reiterated Rating Bank of America Neutral $60.00 to $70.00
2014-12-09 Boost Price Target Stifel Nicolaus Buy $66.00 to $72.00
2014-12-09 Boost Price Target Northland Securities Outperform $65.00 to $70.00
2014-12-08 Boost Price Target Credit Suisse Outperform $57.50 to $75.00
2014-12-04 Initiated Coverage Sanford C. Bernstein Outperform $77.50
2014-11-07 Downgrade Sterne Agee CRT Buy to Neutral $58.00
2014-10-24 Reiterated Northland Capital Outperform $100 to $130
2014-10-24 Reiterated Rating CRT Capital Buy $50.00 to $62.50
2014-10-24 Boost Price Target Stifel Nicolaus Buy $50.00 to $66.00
2014-10-24 Reiterated Rating Morgan Stanley Equal Weight $57.50 to $60.00
2014-10-24 Boost Price Target Northland Securities Outperform $50.00 to $65.00
2014-09-25 Boost Price Target Piper Jaffray Overweight $47.50 to $60.00
2014-09-16 Boost Price Target Canaccord Genuity Buy to Buy $51.50 to $57.00
2014-09-10 Initiated Coverage Sterne Agee CRT Buy $55.00
2014-08-21 Boost Price Target JMP Securities Outperform $48.50 to $60.00
2014-07-31 Boost Price Target Stifel Nicolaus $45.00 to $50.00
2014-07-31 Boost Price Target JPMorgan Chase & Co. $39.00 to $45.00
2014-07-31 Boost Price Target CRT Capital $45.00 to $50.00
2014-07-31 Boost Price Target BMO Capital Markets $42.00 to $44.50
2014-07-30 Reiterated Northland Capital Outperform $90 to $100
2014-07-30 Boost Price Target Canaccord Genuity Buy $48.00 to $51.50
2014-07-30 Reiterated Rating Deutsche Bank Hold $40.50 to $45.00
2014-07-30 Reiterated Rating Barclays Equal Weight $33.50 to $36.50
2014-07-30 Boost Price Target Northland Securities Outperform $45.00 to $50.00
2014-07-30 Boost Price Target Jefferies Group Buy $47.00 to $50.00
2014-07-29 Boost Price Target RBC Capital Sector Perform $35.00 to $39.50
2014-06-11 Upgrade JMP Securities Market Perform to Outperform $48.50
2014-05-22 Boost Price Target CRT Capital Buy $43.50 to $45.00
2014-05-21 Boost Price Target Canaccord Genuity Buy $43.00 to $48.00
2014-05-09 Boost Price Target Leerink Swann $45.00 to $46.50
2014-04-25 Boost Price Target Jefferies Group $47.00
2014-04-25 Boost Price Target Canaccord Genuity Buy $42.00 to $43.00
2014-04-25 Reiterated Rating Stifel Nicolaus Buy $37.50 to $45.00
2014-04-14 Upgrade CRT Capital Fair Value to Buy $39.50 to $43.50
2014-04-14 Boost Price Target Deutsche Bank $31.00 to $39.00
2014-04-14 Upgrade Wells Fargo & Co. Neutral to Buy $82.97 to $90.00
2014-04-14 Upgrade JPMorgan Chase & Co. Underweight to Neutral $30.00 to $39.00
2014-04-14 Reiterated Rating Bank of America Hold $42.50
2014-04-14 Boost Price Target Barclays Equal Weight $32.00 to $33.50
2014-04-14 Upgrade Wells Fargo Neutral to Buy $41.49 to $45.00
2014-03-31 Boost Price Target BMO Capital Markets $31.50 to $33.00
2014-03-24 Reiterated Rating Bank of America Neutral $33.50
2014-03-10 Upgrade Wells Fargo & Co. Market Perform to Outperform
2014-03-10 Upgrade Wells Fargo Market Perform to Outperform
2014-03-07 Boost Price Target CRT Capital Fair Value $36.00 to $39.50
2014-03-06 Boost Price Target Northland Securities $45.00
2014-02-20 Initiated Coverage BTIG Research Neutral
2014-01-28 Boost Price Target Leerink Swann $36.00 to $40.00
2014-01-14 Boost Price Target Canaccord Genuity $37.00 to $39.00
2013-12-10 Lower Price Target Barclays Equal Weight $68.00 to $64.00
2013-12-10 Reiterated Rating Citigroup Inc. Buy $75.00 to $72.00
2013-12-10 Reiterated Rating Canaccord Genuity Buy $76.00 to $74.00
2013-12-10 Downgrade Wells Fargo & Co. Outperform to Market Perform
2013-12-10 Downgrade Wells Fargo Outperform to Market Perform
2013-11-26 Initiated Coverage CRT Capital Fair Value $72.00
2013-11-04 Lower Price Target Deutsche Bank Hold $73.00 to $61.00
2013-10-30 Lower Price Target RBC Capital Sector Perform $75.00 to $60.00
2013-10-30 Boost Price Target Northland Securities Outperform $74.00 to $80.00
2013-10-30 Lower Price Target Barclays Equal Weight $72.00 to $68.00
2013-10-30 Lower Price Target Jefferies Group Buy $85.00 to $80.00
2013-10-30 Lower Price Target Canaccord Genuity Buy $94.00 to $76.00
2013-10-30 Downgrade JPMorgan Chase & Co. Neutral to Underweight $64.00 to $62.00
2013-10-29 Boost Price Target BMO Capital Markets Market Perform $69.00 to $73.00
2013-10-29 Reiterated Rating RBC Capital Hold $75.00
2013-10-29 Boost Price Target Canaccord Genuity Buy $90.00 to $94.00
2013-10-16 Upgrade Citigroup Inc. Neutral to Buy $75.00 to $86.00
2013-10-03 Reiterated Stifel Buy $81 to $82
2013-10-03 Reiterated Rating RBC Capital Hold $75.00
2013-10-03 Boost Price Target Stifel Nicolaus Buy $81.00 to $82.00
2013-07-18 Upgrade Northland Capital Market Perform to Outperform $74
2016-07-12 Reiterated Rating JPMorgan Chase & Co. Buy
2016-06-21 Reiterated Rating Piper Jaffray Overweight $123.00
2016-06-21 Reiterated Rating William Blair Outperform
2016-06-21 Reiterated Rating Piper Jaffray Cos. Overweight $123.00
2016-06-08 Reiterated Rating Credit Suisse Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Verguet Patrick B CVP, Europe 0.12%  (129137) EW /
Wood Larry L CVP, THV Replacement 0.10%  (110001) EW /
Cardis John T 0.09%  (91458) AVY / EW /
BOWLIN MICHAEL R 0.08%  (81751) EW / FTI /
WANG HUIMIN CVP, Japan & Intercontinental 0.08%  (81215) EW /
GARREN BRUCE P CVP, Public Affairs/Special Co 0.05%  (56071) EW /
PYOTT DAVID E I 0.05%  (53582) AGN / ALNY / AVY / BMRN / EW /
MCNEIL BARBARA J 0.04%  (46454) EW /
Abate Thomas M CVP, CFO 0.04%  (43047) EW /
MUSSALLEM MICHAEL A Chairman & CEO 0.04%  (41330) EW /
Lemercier Jean-Luc M CVP, EMEA, Canada, Latin Amer 0.04%  (38840) EW /
VON SCHACK WESLEY W 0.04%  (37306) BK / EW / TDY /
INGRAM ROBERT ALEXANDER 0.03%  (32367) BCRX / CREE / EW / REGN / VRX /
Szyman Catherine M CVP, Critical Care & Vascular 0.03%  (31773) EW / MDT /
Solomon Carlyn D CVP, Critical Care & Vascular 0.03%  (31154) EW / HRC /
BOBO DONALD E JR CVP, Heart Valve Therapy 0.02%  (19767) EW /
LINK WILLIAM J PHD 0.02%  (16000) EW / INGN /
SELLERS ROBERT W.A. VP, Corporate Controller 0.01%  (13092) EW /
Zovighian Bernard J CVP, Surgical Heart Valves 0.01%  (12588) EW /
Redmond Paul C CVP, Global Operations 0.01%  (12534) EW /
Ullem Scott B. CVP, CFO 0.01%  (10968) BERY / BMS / EW /
Gallahue Kieran 0.01%  (9042) CFN / EW / VOLC /
VALERIANI NICHOLAS J 0.01%  (7017) EW / ROKA / RTIX /